Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases
- PMID: 27672289
- PMCID: PMC5028808
- DOI: 10.3748/wjg.v22.i35.7938
Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases
Abstract
Colonic inflammation is required to heal infections, wounds, and maintain tissue homeostasis. As the seventh hallmark of cancer, however, it may affect all phases of tumor development, including tumor initiation, promotion, invasion and metastatic dissemination, and also evasion immune surveillance. Inflammation acts as a cellular stressor and may trigger DNA damage or genetic instability, and, further, chronic inflammation can provoke genetic mutations and epigenetic mechanisms that promote malignant cell transformation. Both sporadical and colitis-associated colorectal carcinogenesis are multi-step, complex processes arising from the uncontrolled proliferation and spreading of malignantly transformed cell clones with the obvious ability to evade the host's protective immunity. In cells upon DNA damage several proto-oncogenes, including c-MYC are activated in parelell with the inactivation of tumor suppressor genes. The target genes of the c-MYC protein participate in different cellular functions, including cell cycle, survival, protein synthesis, cell adhesion, and micro-RNA expression. The transcriptional program regulated by c-MYC is context dependent, therefore the final cellular response to elevated c-MYC levels may range from increased proliferation to augmented apoptosis. Considering physiological intestinal homeostasis, c-MYC displays a fundamental role in the regulation of cell proliferation and crypt cell number. However, c-MYC gene is frequently deregulated in inflammation, and overexpressed in both sporadic and colitis-associated colon adenocarcinomas. Recent results demonstrated that endogenous c-MYC is essential for efficient induction of p53-dependent apoptosis following DNA damage, but c-MYC function is also involved in and regulated by autophagy-related mechanisms, while its expression is affected by DNA-methylation, or histone acetylation. Molecules directly targeting c-MYC, or agents acting on other genes involved in the c-MYC pathway could be selected for combined regiments. However, due to its context-dependent cellular function, it is clinically essential to consider which cytotoxic drugs are used in combination with c-MYC targeted agents in various tissues. Increasing our knowledge about MYC-dependent pathways might provide direction to novel anti-inflammatory and colorectal cancer therapies.
Keywords: Apoptosis; Autophagy; Colon; Colorectal cancer; Inflammation; Therapy; c-MYC.
Conflict of interest statement
Conflict-of-interest statement: All authors declare no conflict of interest.
Figures



Similar articles
-
Activation of c-MYC and c-MYB proto-oncogenes is associated with decreased apoptosis in tumor colon progression.Anticancer Res. 2001 Sep-Oct;21(5):3185-92. Anticancer Res. 2001. PMID: 11848471
-
Contribution of TLR signaling to the pathogenesis of colitis-associated cancer in inflammatory bowel disease.World J Gastroenterol. 2014 Sep 28;20(36):12713-21. doi: 10.3748/wjg.v20.i36.12713. World J Gastroenterol. 2014. PMID: 25278673 Free PMC article. Review.
-
Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage.Nature. 2002 Oct 17;419(6908):729-34. doi: 10.1038/nature01119. Epub 2002 Oct 2. Nature. 2002. PMID: 12384701
-
The c-MYC-ABCB5 axis plays a pivotal role in 5-fluorouracil resistance in human colon cancer cells.J Cell Mol Med. 2015 Jul;19(7):1569-81. doi: 10.1111/jcmm.12531. Epub 2015 Feb 17. J Cell Mol Med. 2015. PMID: 25689483 Free PMC article.
-
MYC in oncogenesis and as a target for cancer therapies.Adv Cancer Res. 2010;107:163-224. doi: 10.1016/S0065-230X(10)07006-5. Adv Cancer Res. 2010. PMID: 20399964 Review.
Cited by
-
Exploration and Validation of a Novel Inflammatory Response-Associated Gene Signature to Predict Osteosarcoma Prognosis and Immune Infiltration.J Inflamm Res. 2021 Dec 9;14:6719-6734. doi: 10.2147/JIR.S340477. eCollection 2021. J Inflamm Res. 2021. PMID: 34916821 Free PMC article.
-
The Identification of Blood Biomarkers of Chronic Neuropathic Pain by Comparative Transcriptomics.Neuromolecular Med. 2022 Sep;24(3):320-338. doi: 10.1007/s12017-021-08694-8. Epub 2021 Nov 5. Neuromolecular Med. 2022. PMID: 34741226 Free PMC article.
-
Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target in Cancers.Cells. 2023 Jun 29;12(13):1745. doi: 10.3390/cells12131745. Cells. 2023. PMID: 37443779 Free PMC article. Review.
-
Sirtuins Affect Cancer Stem Cells via Epigenetic Regulation of Autophagy.Biomedicines. 2024 Feb 7;12(2):386. doi: 10.3390/biomedicines12020386. Biomedicines. 2024. PMID: 38397988 Free PMC article. Review.
-
MASTL induces Colon Cancer progression and Chemoresistance by promoting Wnt/β-catenin signaling.Mol Cancer. 2018 Aug 1;17(1):111. doi: 10.1186/s12943-018-0848-3. Mol Cancer. 2018. PMID: 30068336 Free PMC article.
References
-
- Lazebnik Y. What are the hallmarks of cancer? Nat Rev Cancer. 2010;10:232–233. - PubMed
-
- Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res. 2012;35:1297–1316. - PubMed
-
- Mukherjee B, Morgenbesser SD, DePinho RA. Myc family oncoproteins function through a common pathway to transform normal cells in culture: cross-interference by Max and trans-acting dominant mutants. Genes Dev. 1992;6:1480–1492. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous